Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    DraftFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior review/authorization requirements for oncology medications and supportive agents for Wellcare by Fidelis Care (Medicare) members; affects participating providers dispensing or administering these drugs in pharmacy, physician office, outpatient hospital, or ambulatory settings.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2025
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent (via web portal or phone) for review before dispensing or administration; omissions may result in denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+HCPCS/J/Q codes listed
    ListedBiosimilar preferences
    7/1/2025Effective date

    Coverage and Authorization Criteria

    Authorization requirements

    Covered when ALL of the following are met

    Prior review requirement: Drug is one of the oncology medications or supportive agents listed by HCPCS/J/Q codes in this document

    Requires Evolent review to establish use for a medically accepted indication before dispensing or administration

    Submission completeness: The entire oncology regimen must be submitted to Evolent (including all agents)

    Omitting any part of the regimen may result in denial

    Submission method: Submission via Evolent web portal (my.newcenturyhealth.com) or phone for participating providers; non-participating providers submit to the plan via fax

    Web portal: my.newcenturyhealth.com; Phone: 1-888-999-7713, option 1; Fax for non-participating providers: 1-844-235-5090

    The following items are out of scope and should NOT be submitted to Evolent: antibiotics; bone marrow, stem cell transplants, and CAR‑T cell therapy; controlled substances (e.g., morphine); equipment requests (infusion pumps); genetic lab testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy treatments; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; and immune globulins. Also note the policy instruction to submit the entire oncology regimen to Evolent; omission of any agent may result in denial.

    HCPCS / J / Q Codes

    Listed HCPCS/J/Q CodesmixedCovered
    C9174DATOPOTAMAB DERUXTECAN-DLNK (DATROWAY)
    C9175TREOSULFAN (GRAFAPEX)
    C9293GLUCARPIDASE
    J0185APREPITANT INJ.
    J0207AMIFOSTINE INJ.
    J0594BUSULFAN INJ.
    J0641LEVOLEUCOVORIN INJ.
    J0870IMETELSTAT (RYTELO)
    J0881DARBEPOETIN ALFA NON-ESRD
    J1434FOSAPREPITANT (FOCINVEZ)
    1–10 of 51
    1/6

    Provider Responsibilities and Submission Instructions

    Prior Authorization

    Prior authorization required for listed oncology/supportive agents

    Oncology medications and supportive agents listed by HCPCS/J/Q codes require review by Evolent before dispensing or administration for participating providers; this applies regardless of formulary status and is required to establish use for a medically accepted indication.

    • Applies when drugs are dispensed at a pharmacy or administered in a physician office, outpatient hospital, or ambulatory setting.
    Note

    HCPCS/J-codes for oral specialty drugs listed (prior auth implication not separately specified)

    The document lists multiple HCPCS/J-codes for oral specialty drugs (including J7520, J7527, J8501, J8530, J8565, J8600, J8999, J9216, Q0155) effective 7/1/2025 for Wellcare by Fidelis Care; the chunks containing these code lists do not specify separate prior authorization mechanics beyond inclusion on the Evolent review lists.

    • Examples include J7520 SIROLIMUS ORAL; J7527 EVEROLIMUS ORAL; J8501 APREPITANT ORAL; J8530 CYCLOPHOSPHAMIDE ORAL; J8999 (multiple oral agents).

    Where Prior Review Applies

    Prior Authorization

    Review required at pharmacy, office, infusion center, or hospital outpatient

    All listed agents require review before being dispensed at a pharmacy or administered in a physician office, outpatient hospital, or ambulatory (infusion center) setting for members of all ages.

    • Applies to medical or pharmacy benefit agents when provided in these sites of care.

    Biosimilar Preferences

    Billing Rule

    Trastuzumab — Trazimera preferred (medical benefit)

    Trazimera is listed as the preferred medical-benefit biosimilar for trastuzumab; multiple trastuzumab products (Herceptin and biosimilars) are listed under pharmacy benefit.

    • Providers should send preferred trastuzumab agents to Evolent for review.
    Billing Rule

    Bevacizumab — Mvasi and Zirabev preferred (medical benefit)

    Mvasi and Zirabev are listed as preferred medical-benefit biosimilars for bevacizumab; Avastin and biosimilars are listed under the pharmacy benefit.

    • Providers should send preferred bevacizumab agents to Evolent for review.

    Key Definitions

    Participating providers
    DefinitionProviders contracted with the plan (participating providers).
    Primary responsibilityParticipating providers must submit reviews to Evolent prior to dispensing or administering listed agents.
    Submission channelsEvolent web portal at my.newcenturyhealth.com or phone 1-888-999-7713, option 1; non-participating providers submit to the plan by fax (1-844-235-5090).

    Step Therapy / Preferred Agents

    Drug class / reference drugPreferred biosimilar(s) (medical benefit)Preferred biosimilar(s) (pharmacy benefit)Provider action
    Erythropoiesis‑stimulating agentsRetacrit (medical benefit)Procrit (pharmacy benefit)Send preferred agent to Evolent for review as part of the complete regimen submission
    TrastuzumabTrazimeraHerceptin; Herceptin Hylecta; Herzuma; Kanjinti; Ogivri; Ontruzant; TrazimeraSend preferred agent to Evolent for review as part of the complete regimen submission
    BevacizumabMvasi; ZirabevAvastin; Mvasi; ZirabevSend preferred agent to Evolent for review as part of the complete regimen submission
    Hematopoietic agentsZarxioZarxioSend preferred agent to Evolent for review as part of the complete regimen submission

    Background

    This policy lists oncology medications and supportive agents (including antiemetics, growth factors, hematopoietic agents, and other supportive drugs) that require prior review by Evolent before dispensing or administration for participating providers. The requirement applies to agents identified by HCPCS/J/Q codes in the document and covers medications provided via pharmacy benefit or medical benefit across care settings (pharmacy, physician office, outpatient hospital/infusion center). Providers must submit the complete oncology regimen to Evolent for review; partial or incomplete submissions may result in denial. Submission channels and contact details for Evolent (web portal or phone) are provided in the document.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Wellcare by Fidelis Care)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2025
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent (via web portal or phone) for review before dispensing or administration; omissions may result in denial.
    SourceLink
    On This Page
    Coverage and Authorization CriteriaHCPCS / J / Q CodesProvider Responsibilities and Submission InstructionsWhere Prior Review AppliesBiosimilar PreferencesKey DefinitionsStep Therapy / Preferred AgentsBackground

    These document chunks do not list explicit coverage exclusions for the oncology agents described elsewhere; they contain code listings and an effective date. The oral specialty J‑code group (for example codes such as J7520, J7527, J8501, J8530, J8565, J8600, J8655, J8670, J8999, J9216, Q0155) and associated agents are presented as listed for Wellcare by Fidelis Care and are effective 7/1/2025. Refer to the coding section for the full code lists and the effective date for Wellcare by Fidelis Care.

    Listed Oral/Other Codes (J7520, J8999 group)mixedCovered
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL (5 MG, suspension, tripak)
    J8530CYCLOPHOSPHAMIDE ORAL
    J8565GEFITINIB
    J8600MELPHALAN ORAL
    J8999MULTIPLE ORAL ONCOLOGY AGENTS (long list)
    Listed Q-codesmixedCovered
    Q2017TENIPOSIDE 50 MG
    Q2043SIPULEUCEL-T AUTO CD5+
    Q2050LIPOSOMAL DOXORUBICIN
    Q5101FILGRASTIM-SNDZ
    Q5106EPOETIN ALFA-EPBX (RETACRIT BIOSIMILAR)
    Listed HCPCS/J-codes (grouped from chunk 18)HCPCS
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL 5 MG / APREPITANT ORAL SUSPENSION / APREPITANT TRIPAK 125-80 MG
    J8530CYCLOPHOSPHAMIDE ORAL
    J8565GEFITINIB
    J8600MELPHALAN ORAL
    J8655NETUPITANT/PALONOSETRON ORAL
    J8670ROLAPITANT, ORAL
    J8999Multiple oral specialty drugs listed under J8999 (see document for many specific agents)
    J9216INTERFERON GAMMA 1B
    1–10 of 11
    1/2
    Listed HCPCS/J-codes (grouped from chunk 19)HCPCS
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL 5 MG / APREPITANT ORAL SUSPENSION / APREPITANT TRIPAK 125-80 MG
    J8530CYCLOPHOSPHAMIDE ORAL
    J8565GEFITINIB
    J8600MELPHALAN ORAL
    J8655NETUPITANT/PALONOSETRON ORAL
    J8670ROLAPITANT, ORAL
    J8999Multiple oral specialty drugs listed under J8999 (additional agents listed in chunk 19)
    Listed HCPCS/J-codes (grouped from chunk 20)HCPCS
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL 5 MG / APREPITANT ORAL SUSPENSION / APREPITANT TRIPAK 125-80 MG
    J8530CYCLOPHOSPHAMIDE ORAL
    J8565GEFITINIB
    J8600MELPHALAN ORAL
    J8655NETUPITANT/PALONOSETRON ORAL
    J8670ROLAPITANT, ORAL
    J8999Multiple oral specialty drugs listed under J8999 (additional agents listed in chunk 20)
    J9216INTERFERON GAMMA 1B
    Listed HCPCS/J-codes (grouped from chunk 21)HCPCS
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL 5 MG / APREPITANT ORAL SUSPENSION / APREPITANT TRIPAK 125-80 MG
    J8530CYCLOPHOSPHAMIDE ORAL
    J8565GEFITINIB
    J8600MELPHALAN ORAL
    J8655NETUPITANT/PALONOSETRON ORAL
    J8670ROLAPITANT, ORAL
    J8999Multiple oral specialty drugs listed under J8999 (see chunk 21)
    Effective date
    Effective date7/1/2025
    Applies toListings and code groups effective for Wellcare by Fidelis Care Medicare
    ScopeAll HCPCS/J/Q codes and listed oral specialty agents in this document
  1. Effective date: 7/1/2025 (Wellcare by Fidelis Care).
  2. Prior Authorization

    Send preferred biosimilars to Evolent for review

    Preferred biosimilar agents are identified for several drug classes; providers are instructed to send preferred agents to Evolent for review as part of the authorization process.

    • Examples: Trazimera preferred (medical benefit) for trastuzumab; Mvasi and Zirabev preferred (medical benefit) for bevacizumab; Ruxience and Truxima preferred (medical benefit) for rituximab.
    Step Therapy

    No step therapy rules specified

    No step therapy rules are defined in the listed chunks; the policy notes biosimilar preferences but does not establish any step therapy sequencing or failure criteria.

    Documentation Required

    Submission channels for authorization requests

    Requests for review may be submitted via Evolent's web portal (my.newcenturyhealth.com) or by calling 1-888-999-7713, option 1; non-participating providers must submit requests to the plan by fax at 1-844-235-5090.

    • Portal: my.newcenturyhealth.com
    • Phone: 1-888-999-7713, option 1
    • Non-participating provider fax: 1-844-235-5090
    Documentation Required

    No additional documentation or prior authorization instructions in code listing sections

    The chunks containing lists of oral HCPCS/J-codes do not include additional documentation or prior authorization submission instructions beyond the general portal/phone/fax guidance.

    Denial Risk

    Submit entire oncology regimen; omissions may cause denial

    Submit the complete oncology regimen to Evolent — omission of any part of the regimen when submitting may result in a denial.

    • Include all agents in the regimen (supportive and anti-cancer agents) in the single submission to Evolent.
    Note

    No other provider actions specified in these code-list chunks

    These chunks consist primarily of HCPCS/J-code lists and an effective date; they do not specify additional provider actions beyond listing the codes themselves.

    Billing Rule

    Rituximab — Ruxience and Truxima preferred (medical benefit)

    Ruxience and Truxima are listed as preferred medical-benefit biosimilars for rituximab; multiple rituximab products and biosimilars are listed under the pharmacy benefit.

    • Providers should send preferred rituximab agents to Evolent for review.